Celgene Corporation

Celgene — Merger or Acquisition (March 2019)

46 slides from Celgene's merger presentation, Mar 6, 2019

  1. Slide 1: Transaction Update Investor Presentation March 2019

    Transaction Update INVESTOR PRESENTATIONMARCH 2019

  2. Slide 2: Important Information For Investors And Stockholders

    Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securiti

  3. Slide 3: Cautionary Statement Regarding Forward-Looking Statements

    Cautionary Statement Regarding Forward-Looking StatementsThis communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking

  4. Slide 4: Executive Summary

    Executive Summary The Celgene acquisition has clear strategic rationale and represents a compelling value propositionEnhanced product leadership and pipeline: Combined company will be #1 in oncology, top 5 in immunology and inflammation, #1 in cardiovascular; 9 products over $1Bn in annual sales; 6

  5. Slide 5: The Celgene Acquisition Has Clear Strategic Rationale and Represents a Compelling Value Proposition

    The Celgene Acquisition Has Clear Strategic Rationale and Represents a Compelling Value Proposition

  6. Slide 6: Consistent with our strategy of delivering value for shareholders

    Consistent with our strategy of delivering value for shareholders by enhancing core franchises and delivering innovative therapies for patientsCelgene pipeline includes 5 differentiated late-stage assets with low clinical risk, expected near-term approvals and incremental value creationExpanded earl

  7. Slide 7: Strengthened Position in Both the Near- and Long-Term

    Creates new company with increased scale while maintaining focus and agilityCreates leading Oncology company and adds a premier commercial hematology businessImmunology & Inflammation franchise with greater commercial scale and pipeline depthStronger combined company to address eventual loss-of-excl

  8. Slide 8: Celgene Provides Late Stage Products With Near-Term Approvals and Relatively Low Clinical Risk

    Celgene Provides 5 Late Stage Products With Near-Term Approvals and Relatively Low Clinical RiskBMS Projected Total Sales from “Big 5” in 2025 Consistent with Street Forecasts Ph 3 / PivotalComplete CVR Tied to Near Term Approval Key Benefits Current Status  First- and Best-in-class novel anemia dr

  9. Slide 9: Celgene Offers Leading Capabilities in Cell Therapy and Differentiated Late-Stage CAR-T Assets

    Celgene Offers Leading Capabilities in Cell Therapy and 2 Differentiated Late-Stage CAR-T AssetsTransformational Modality with Unprecedented Efficacy Cell therapy market expected to grow from ~$1Bn in 2019 to >$15Bn in 2024¹Growing expectations for cell therapy given superior efficacy, expected evol

  10. Slide 10: Liso-cel: Potential Best-in-Class anti-CD19 CAR-T for B Cell Malignancies

    CLL Liso-celPotential Best-in-Class anti-CD19 CAR-T for B Cell Malignancies Broad Clinical Development Plan to Advance into Earlier Lines and Additional Indications PIVOTAL PHASE II PHASE I TRANSCEND WORLD (Ph II 3L+ R/R EU and Japan; 2L R/R transplant ineligible) DLBCL PLATFORM (Ph I/II 3L+ R/R com

  11. Slide 11: bb2121 Anti-BCMA CAR-T with Transformational Efficacy in Late Line RRMM

    bb2121 Anti-BCMA CAR-T with Transformational Efficacy in Late Line RRMM Potential U.S. Approval 2H 2020 Standard Treatment Regimens Across Multiple Myeloma (%) Emerging bb2121 Profile ORR 69%-82% ORR 59%-91% ORR 29% - 59% ORR 96% N= 22 Complete Response VGPR PR PIVOTAL PHASE II PHASE I Phase II stud

  12. Slide 12: Celgene Provides a Significantly Expanded Early Stage Pipeline and New Technology Platforms

    Celgene Provides a Significantly Expanded Early Stage Pipeline and New Technology Platforms Transaction provides BMS with >20 Phase 1 and 2 programsNew capabilities in cell therapy and protein homeostasisStrongest position in BCMA: 5 programs total, first expected BCMA launch product (bb2121), and 3

  13. Slide 13: Significant Value Creation Opportunity From Celgene Pipeline

    Significant Value Creation Opportunity From Celgene Pipeline More than 80% of transaction value supported by currently marketed products and synergies aloneValue of currently marketed products reflects Revlimid assumptions which are more conservative than those of sell-side analystsImplied cost of “

  14. Slide 14: Celgene Provides a 'String-of-Pearls' in One Transaction at an Attractive Valuation

    Celgene Provides a ‘String-of-Pearls’ in One Transaction and at an Attractive Valuation Traditional ‘string-of-pearls’ strategy difficult, longer to execute and at significant premiumsRequires successfully identifying and winning multiple potentially competitive processesStreet estimates for Celgene

  15. Slide 15: Analysis Based on Conservative, Risk-Adjusted Projections for Celgene

    Analysis Based on Conservative, Risk-Adjusted Projections for Celgene Source: Capital IQ, SEC filingsCapital IQ median as of 01/02/2019 Consensus1 Celgene Blended Mgmt. Case BMS Projections for Celgene Extensive due diligence conducted on Revlimid IP estateBMS base commercial assumptions below both

  16. Slide 16: Significant Near-Term Free Cash Flow Generation

    Significant Near-Term Free Cash Flow Generation 2020E – 2023E Pro Forma BMS + Celgene Cumulative Free Cash Flow In $Bn Source: SEC filings Transaction significantly enhances cash flow generation, enabling rapid deleveraging and providing flexibility for continued business development and return of c

  17. Slide 17: ~$2.5Bn of Cost Synergies Provide for Over $20Bn in Value

    ~$2.5Bn of Cost Synergies Provide for Over $20Bn in Value Sources of Synergies % of Total Synergies Source: SEC Filings Overview of SynergiesSynergies represent $2.5Bn in sustainable long-term cost savings Represents ~13% of combined company OpEx; Well within biopharma precedents To be generated fro

  18. Slide 18: BMS Equity Issued at Favorable Relative Valuation, Creating Value for BMS Shareholders

    BMS Equity Issued at Favorable Relative Valuation, Creating Value for BMS Shareholders 1.3x 1.8x BMS / Celgene Natural Exchange Ratio at Two-Year Lows1 January 1, 2017 to January 2, 2019 Opportunistic timing given favorable relative valuation of BMS versus Celgene equity Source: Capital IQ, SEC Fili

  19. Slide 19: Highly Attractive Purchase Price

    Highly Attractive Purchase Price Pre-Announcement Celgene Analyst Price Targets Higher than Offer PriceSeptember 3, 2018 to January 2, 2019 6.7x Celgene NTM P/E 1 Source: Capital IQConsensus estimate; not burdened by stock-based compensationExcludes CVR valueTransaction was withdrawnBased on final p

  20. Slide 20: Combined Company to Grow Revenues in Each Year Through 2025

    Combined Company to Grow Revenues in Each Year Through 2025 Pro Forma Revenue are pro forma for the transaction and for 2019 are based on full year contribution for purposes of comparison. These figures are based on numerous assumptions and estimates, including information provided to the Company by

  21. Slide 21: Significantly Expanded Earnings Power of Combined Company

    Significantly Expanded Earnings Power of Combined Company Source: SEC filings BMS Pro Forma Net Income BMS Standalone Net Income Transaction more than 40% accretive to EPS in first full yearAccretive to EPS in all years though 2025Significant free cash flow from combination to provide flexibility fo

  22. Slide 22: Celgene Enhances Overall Business Profile of BMS

    Celgene Enhances Overall Business Profile of BMS Meaningfully enhanced product diversification and margin profile Includes run-rate synergies of $2.5Bn Top 3 BMS Products as % of Standalone and Pro Forma Revenue 2025E Revenue Standalone vs. Pro Forma Margins 2018A Non-GAAP Operating Income Margin

  23. Slide 23: Bristol-Myers Squibb Has a Strong Track Record of Financial and Operational Outperformance

    Bristol-Myers Squibb Has a Strong Track Record of Financial and Operational Outperformance

  24. Slide 24: Robust Record of BMS Operating and Financial Performance

    Robust Record of BMS Operating and Financial Performance While we are not satisfied with recent share price performance, largely driven by dynamics in first-line lung cancer, the Bristol-Myers Squibb team has generated a track-record of strong operating and financial results over the last five years

  25. Slide 25: Diversified Specialty BioPharma

    Diversified Specialty BioPharma Best of BIOTECH Best of PHARMA INNOVATION Focused and Integrated The Best PEOPLE helping patients in their fight against serious disease Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a

  26. Slide 26: Proven Success in Transitioning Portfolio Over Time

    Proven Success in Transitioning Portfolio Over Time BMS Historical Total Sales ($Bn) Contribution of Sales (%) +$14Bn Established Brands Other Prioritized Brands Prioritized Brands Launched Since 2011 Other +$2Bn ($9Bn) +$6Bn Management has a proven track record of success in transitioning a mature

  27. Slide 27: BMS Has Outperformed Peers Across Multiple Metrics Over Last 5 Years

    Revenue Growth 1 BMS Has Outperformed Peers Across Multiple Metrics Over Last 5 Years Adj. Operating Margin Improvement 1, 2 Adj. EPS Growth1 % CAGR Change in bps; 2013 - 2018 % CAGR 3 3 3 Sources: Company filings & Capital IQMetrics shown based on as adjusted reported financials; historical financi

  28. Slide 28: Track Record of Portfolio Development Through Internal Investment and Acquisitions

    Products sourced through acquisitionof for $1.8Bn $6.7B $1.3B $2.7B $2.0B Track Record of Portfolio Development Through Both Internal Investment and Acquisitions Celgene acquisition is an extension of historical balanced approach to delivering new medicines to patients INTERNAL EXTERNAL 2018 Sales:

  29. Slide 29: Commercial Excellence Extends Across Multiple Strategic Objectives

    Eliquis 3rd to enter the novel anticoagulant (NOAC) market in 2012Able to push to the leading position through solid execution and a differentiated clinical profile#1 NOAC$6.4Bn of Eliquis sales in 2018 showing 32% growth Successfully launched OpdivoDespite being 2nd to enter US anti PD-1 market at

  30. Slide 30: I-O Commercial and Development Success

    I-O Commercial and Development Success Top Oncology Products: Cumulative Sales in 4 Years Post Launch US Sales ($Bn) Approvals Post-Launch 0 2 4 6 8 10 Opdivo Avastin Taxotere 12 14 16 in Yearsin the U.S. Approvals 16 4 Source: IQVIA NSP $ Sales US only

  31. Slide 31: BMS Continues to Lead in Key Tumors Where Opdivo is Approved

    Lung 2L Leadership with 28% BMS I-O share3L+ SCLC Leadership with 68% BMS I-O share Melanoma 1L Leadership with 60% BMS I-O shareAdjuvant Leadership with 77% BMS I-O share Renal cell Carcinoma 1L Leadership with 44% BMS I-O share2L Leadership with 52% BMS I-O share Head & Neck Post platinum 18% BMS

  32. Slide 32: Eliquis Has Become #1 NOAC Globally

    Eliquis Annual Sales $Bn; 2013 - 2018 5 Year CAGR: +113% +430% +140% +80% +46% +32% Annual Growth: #1 NOAC(Mar’15) #1 OAC(Feb’16) Evolution of OAC Market Share in Atrial Fibrillation (AF)1 January 2013 – September 2018 Chart represents New-to-Brand (Naïve+Switch) Rxs (NBRx). Eliquis, Xarelto, Pradax

  33. Slide 33: Commitment to Margin Expansion With Ongoing Operating Model Transformation

    Commitment to Margin Expansion With Ongoing Operating Model Transformation Company operating model transformation progress continues – originally announced 3Q 2016Significant operational changes have been successfully implemented while continuing to maintain favorable R&D productivity metrics and be

  34. Slide 34: Strong Track Record of Financial Results

    Net Sales, $Bn Strong Track Record of Financial Results… $16.4 $15.9 $16.6 $19.4 $20.8 $22.6 CAGR6.6% Adj. Operating Income1, $Bn CAGR13.1% Adj. Operating Margin1 % Adj. EPS +725bps 21.1% 21.8% 23.4% 25.9% 25.0% 28.3% $3.5 $3.5 $3.9 $5.0 $5.2 $6.4 $1.82 $1.85 $2.01 $2.83 $3.01 $3.98 CAGR16.9% Source

  35. Slide 35: With a High Degree of Execution Consistency

    …With a High Degree of Execution Consistency… Adjusted EPS Results Have Beat or Met Consensus Expectations in 92% of Quarters Since the Beginning of 2013 (22/24 Quarters)1 Quarterly EPS ($ / share); 1Q 2013 – 4Q 2018                         Sales Have Beat or Met Consensus Ex

  36. Slide 36: And Sustained Growth in Key Global Franchises

    Immuno-Oncology (Opdivo + Yervoy) Quarterly Sales Since the Beginning of 2013 Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018 Eliquis Quarterly Sales Since the Beginning of 2013 Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018 Y-o-Y Growth: Y-o-Y Growth: Source: Company Filings …And Sustained Growth in Key Global

  37. Slide 37: The Board and Management Team Conducted a Robust Process and Diligence

    The Board and Management Team Conducted a Robust Process and Diligence and Are Committed to a Successful Integration

  38. Slide 38: BMS has a regular process to evaluate strategic opportunities

    BMS has a regular process to actively evaluate strategic opportunities to create long-term value for shareholdersPrioritized more than 20 opportunities in early 2018, and narrowed down over time to focus on the 7 best opportunitiesOpportunities included 'string-of-pearls' strategies as well as other

  39. Slide 39: The Celgene Acquisition Resulted From a Robust Strategic Review

    7 companies prioritized for deep dive analysis based on additional financial and strategic criteriaIncluded both transformational and 'string-of-pearls' 77 biopharma opportunities identified;22 prioritized for assessment based on strategic fit Celgene identified as lead opportunity based on strategi

  40. Slide 40: Robust Diligence Process on Celgene Opportunity

    Robust Diligence Process on Celgene Opportunity Work led by ~25 BMS senior leaders and their teams across functional areas and supported by subject matter experts and financial and legal advisorsConducted assessment of markets and drivers of key assets and indications based on competitive intel, pri

  41. Slide 41: Revlimid IP Was a Key Focus of Due Diligence

    Revlimid IP Was a Key Focus of Due Diligence BMS and its legal advisors conducted an extensive review of the entire Revlimid patent estateReceived access to this non-public information prior to the beginning of other confidential diligence Reviewed the non-public, unredacted Natco agreementExtensive

  42. Slide 42: Post-NDA Diligence Process Consistent With Precedent Transactions

    Post-NDA Diligence Process Consistent With Precedent Transactions NDA Signed IP Diligence Begins Management Presentation 11/23/18 41 days prior to announcement 11/28/18 36 days prior to announcement 12/13/18 21 days prior to announcement All Completed Acquisitions of Public Biopharma Companies Over

  43. Slide 43: BMS is Focused and Committed to a Successful Integration

    BMS is Focused and Committed to a Successful Integration Complementary nature of businessesNot a traditional big pharma, high-overlap dealStrong team in place to manage integrationTop priority of leadershipFull-time integration leads appointed for each company and for each functional areaExperienced

  44. Slide 44: Complementary Organizations – Streamlined Integration Process

    Complementary Organizations – Streamlined Integration Process BMS Celgene Commentary Source: Company filings and websitesBMS’s principal executive office per SEC filings is New York, NYPro forma for divestiture of 1,500 USPA employees; BMS reported 23,300 employees in its 2018 10KPro forma for dives

  45. Slide 45: Directors and Experience

    Director Director Since Experience Giovanni Caforio, M.D. 2014 Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Vicki L. Sato, Ph.D. 2006 Lead Independent Director, Bristol-Myers Squibb; Independent Chairman of the Board, Denali Therapeutics; Former Professor of Management Pra

  46. Slide 46: Board and Governance – Relevant Experience and Accountability

    Board and Governance – Relevant Experience and Accountability 10 / 11 directors independent (91%)Strong Lead Independent Director with robust responsibilities and oversight5 new independent directors added in the past 3 years1 Average tenure of 5.5 years vs. S&P average tenure of 8.1 yearsAnnually e

Celgene — Merger or Acquisition (March 2019) on 6ix